Auris Medical Holding (EARS) Misses Q1 EPS by 6c

Auris Medical Holding (NASDAQ: EARS) reported Q1 EPS of ($0.28), $0.06 worse than the analyst estimate of ($0.22).

"Auris Medical continued to make strong progress in the first months of 2015," commented Thomas Meyer, the Company's founder, Chairman and CEO. "Enrollment into our AM-101 Phase 3 trials in the treatment of acute inner ear tinnitus advanced well, and through our recent equity raise we laid the groundwork for moving forward with an expanded AM-111 late-stage clinical development program. The treatment of acute inner ear hearing loss with AM-111 addresses an important unmet medical need and represents a substantial commercial opportunity for Auris Medical."

For earnings history and earnings-related data on Auris Medical Holding (EARS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery